Compare CSTL & CMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | CMP |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 781.2M |
| IPO Year | 2019 | 2003 |
| Metric | CSTL | CMP |
|---|---|---|
| Price | $38.83 | $20.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $38.67 | $20.00 |
| AVG Volume (30 Days) | ★ 439.7K | 338.5K |
| Earning Date | 11-03-2025 | 12-08-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $343,530,000.00 | ★ $1,225,200,000.00 |
| Revenue This Year | $1.69 | $12.05 |
| Revenue Next Year | N/A | $4.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.15 | 7.27 |
| 52 Week Low | $14.59 | $8.60 |
| 52 Week High | $40.61 | $22.69 |
| Indicator | CSTL | CMP |
|---|---|---|
| Relative Strength Index (RSI) | 71.92 | 68.93 |
| Support Level | $38.69 | $18.56 |
| Resistance Level | $40.54 | $19.30 |
| Average True Range (ATR) | 1.58 | 0.70 |
| MACD | -0.18 | 0.32 |
| Stochastic Oscillator | 75.59 | 90.98 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.